Clinical trials: SBRT
Prostate Cancer
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.
- Trial name
- NCT03294889
- Testing
- Stereotactic body radition (SBRT)
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University Hospital, Geneva
Hepatocellular Carcinoma (HCC)
SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
SBRT combined with dual PD-1/CTLA-4 blockade (iparomlimab and tuvonralimab, QL1706) and bevacizumab may provide complementary local and systemic antitumor activity in hepatocellular carcinoma (HCC).
- Trial name
- NCT07882056
- Testing
- Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Squamous Cell Carcinoma
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter phase II clinical trial comparing the efficacy and safety of low-dose radiation therapy and stereotactic body radiation therapy combined with PD-1 inhibitor (sintilimab)…
- Trial name
- NCT06121505
- Testing
- low-dose radiation therapy and stereotactic body radiation therapy, chemotherapy, Sintilimab
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma.
- Trial name
- NCT05626569
- Testing
- PD-1 combined with SBRT
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Melanoma, Ocular, Melanoma, Cutaneous
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with…
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal
- Trial name
- NCT05169957
- Testing
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bone Metastases, Prostate Cancer
Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief
Radiation therapy has been shown to be very effective at relieving pain caused by bone metastases. However, certain types of cancers such as prostate, breast, kidney, and melanoma can have resistance to radiation, making…
- Conditions
- Bone Metastases, Prostate Cancer, Breast Cancer, Renal Cell Carcinoma
- Trial name
- SOLAR-P (NCT04177056)
- Testing
- SBRT
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Hamilton Health Sciences Corporation
Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma
Notable-HCC is a phase Ib study of neoadjuvant stereotactic body radiotherapy (SBRT) plus Programmed cell death-1 (PD-1, Tislelizumab, BeiGene) prior to hepatic resection in patients with resectable HCC.
- Trial name
- Notable-HCC (NCT05185531)
- Testing
- PD-1 plus stereotactic body radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
Pancreatic Cancer, Pancreatic Adenocarcinoma
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal…
- Trial name
- NCT04130399
- Testing
- Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
- Where
- United States
- Sponsor
- Indiana University
Prostate Cancer
Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt
Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time and by (ii) enabling a safe delivery…
- Trial name
- HypoF-SBRT (NCT06330909)
- Testing
- Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT, Radiotherapy (RT) Arm B - IMRT/IGRT
- Where
- Germany
- Volunteers
- 374 people
- Sponsor
- University Hospital Freiburg
Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume
Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer
*Rationale : Active surveillance of prostate cancer helps to avoid the morbidity associated with curative radical prostatectomy /radiotherapy in patients with early stage disease.
- Conditions
- Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume, CAPRA SCORE ≤5
- Trial name
- TOPPGUN-RS (NCT07152067)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Belgium
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body.
- Trial name
- NCT02296229
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Renal Cancer
Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial
The study objective is to evaluate the use of Stereotactic Body Radiotherapy (high dose of radiation in a few fractions) to cure primary renal cancer in those patients that are not indicated to surgery (high risk of…
- Trial name
- NCT07299357
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- 2 sites in Italy
- Volunteers
- 53 people
- Sponsor
- Istituto Clinico Humanitas
Ventricular Tachycardia, Chagas Disease
SBRT in Chagas Disease Ventricular Tachycardia
This is an observational study of 10 Chagas Disease patients with Ventricular Tachycardia that have failed prior catheter ablation or have this procedure contraindicated due to clinical status.
- Conditions
- Ventricular Tachycardia, Chagas Disease, Cardiac Arrhythmia
- Trial name
- NCT04984265
- Testing
- Stereotactic Body Radiation Therapy
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- University of Sao Paulo General Hospital
Child-Pugh Class A, Child-Pugh Class B
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
- Trial name
- NCT02507765
- Testing
- Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Impact of 5-fraction Stereotactic Partial Breast Irradiation and Whole Breast Irradiation on Cosmetic Outcome and Patient-reported Outcomes in Early-stage Breast Cancer
This study aim to investigate the effect of 5-fraction stereotactic partial breast irradiation and whole breast irradiation on patient-reported outcomes, cosmetic outcome, and breast tissue fibrosis in early-stage breast cancer.
- Trial name
- NCT03568981
- Testing
- Partial breast irradiation, Whole breast irradiation
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Gastrointestinal Neoplasms
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal…
- Trial name
- NCT06301828
- Testing
- Envafolimab Injection, Endostar
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Breast Cancer
Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery
This is a prospective pilot study investigating the safety and efficacy of stereotactic body radiation therapy (SBRT) as a treatment for breast cancer in patients who do not get surgery.
- Trial name
- SBRT BREAST (NCT04532177)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stony Brook University
Stage II-III Non-small Cell Lung Cancer
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable…
- Trial name
- neoR-TORCH (NCT06437977)
- Testing
- SBRT, Toripalimab
- Where
- China
- Volunteers
- 478 people
- Sponsor
- Shanghai Chest Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Prostate Cancer (Adenocarcinoma), Erectile Abnormalities
PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.
- Conditions
- Prostate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction Male
- Trial name
- PRIAPUS-PCa (NCT07460726)
- Testing
- SBRT combined with ADT
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- CancerCare Manitoba